Sign in to view content

Primary Analysis Results of the Phase 3 Archway Trial of the Port Delivery System With Ranibizumab (PDS) for Patients With Neovascular AMD

Peter A. Campochiaro, MD

Video
Published 2020

Related

Diabetic Retinopathy Progression in Anti-VEGF Versus Fluocinolone Acetonide Implant Treated Eyes Who Are Lost to Follow-up
Caesar K. Luo, MD, FASRS
Annual Meeting Talks
2020
Safety and Efficacy of Switching to Biosimilar Ranibizumab in Eyes Initially Treated With Reference Ranibizumab for nAMD, DME, or RVO
Nikhil K Bommakanti, MD
Annual Meeting Talks
2024
Short-term Effects of COVID-19-Related Deferral of Intravitreal Injection Visits
William E. Smiddy, MD
Annual Meeting Talks
2021

Category: AMD-Neovascular

See more